Southern African HIV Clinicians Society Guidelines for Antiretroviral Therapy in Adults: 2023 Update
The Southern African HIV Clinicians Society has released their 2023 updated guidelines for antiretroviral therapy in adults. This article contains Modules 2 to 5, covering the available drugs in Southern Africa.
Modern Medicine – Issue 4 2023
Pre-exposure Prophylaxis Cuts HIV Risk
In 2015, recognising that HIV pre-exposure prophylaxis (PrEP) has potential population-wide benefits, the World Health Organisation’s (WHO) guidelines recommend that PrEP should be offered as a choice to people who are at substantial risk of HIV infection as part of a combination HIV prevention programme. Previously, PrEP was only recommended for certain key affected populations such as sex workers, men who have sex with men and people who inject drugs.
Modern Medicine – Issue 4 2019
Adult Antiretroviral Therapy Guidelines
The HIV guidelines by Meintjies et al. (2017) are an update to those published in the Southern African Journal of HIV Medicine in 2014 and an update to guidelines regarding when to initiate antiretroviral therapy (2015). Since the release of the previous guidelines, the scale-up of antiretroviral therapy (ART) in southern Africa has continued. New antiretroviral drugs have become available with improved efficacy, safety and robustness.
Modern Medicine – June/July 2018
First-line HIV Treatment Guidelines – MM1605
Currently, there is no effective vaccine against or efficient method of cure for HIV infection; however, numerous antiretroviral medicines have been devised to combat the progression of HIV infection into AIDS. Because no drug has proven to be exceedingly effective individually and the dynamic HIV genome is capable of rapidly developing drug resistance, the use of multiple drug classes each addressing a different aspect of HIV infection is preferred.
Modern Medicine – May 2016
World’s Most Portable Molecular Diagnostics System Unveiled – MM1511
Cepheid and FIND have unveiled the GeneXpert & Omni, the world’s most portable molecular diagnostics system enabling unprecedented access to accurate, fast and potentially lifesaving diagnosis for patients suspected of TB, HIV and Ebola in even the most remote areas of the world.
Modern Medicine – November 2015
Qualitative 90-Minute Test Enables Early HIV Detection in High-Risk and Paediatric Patients – MM1505
Cepheid and FIND announced last month that Xpert® HIV-1 Qual, a qualitative 90-minute molecular HIV test, has achieved CE-IVD status under the European Directive on In Vitro Diagnostic Medical Devices. The test runs on the Cepheid GeneXpert® System, the world’s leading molecular diagnostic platform with over 8000 systems deployed globally in both developed and emerging market countries.
Modern Medicine – May 2015
Cepheid’s Xpert HIV-1 Viral Load Test Gets European Approval – MM1502
Quantitative test for rapid measurement of the HIV-1 Viral Load in plasma delivers individual results in about 90 minutes.
Modern Medicine – February 2015
HIV Infection as a Chronic Disease: Optimising Outcomes – MM1502
Provided they receive regular care, the life expectancy of patients newly diagnosed with HIV infection in the developed world can approach that of the general population. For most people this will mean lifelong daily medication with a combination of antiretroviral drugs.
Modern Medicine – February 2015
Start ART at CD4 ≤500 to Save Millions More Lives: WHO Guidelines – MM1309
The extensive global expansion of access to HIV treatment is transforming not only the HIV epidemic but also the entire public health landscape. In 2012, 1.6m more people were receiving antiretroviral therapy (ART) in low- and middle-income countries compared to a year earlier, with the greatest increases occurring in the WHO African region. In 2002, 300 000 people received ART in low- and middleincome countries which increased to 9.7m in 2012. The target is to allow 15m people access to ART by 2015.
Modern Medicine – September 2013
